Clinical trials: Atopic Dermatitis (AD)
Moderate to Severe Atopic Dermatitis
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to…
- Trial name
- REZOLVE-AD (NCT06136741)
- Testing
- Rezpegaldesleukin
- Where
- 107 sites in United States, Australia and 8 more
- Volunteers
- 396 people
- Sponsor
- Nektar Therapeutics
Atopic Dermatitis
A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India
The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in India.
- Trial name
- NCT05375929
- Testing
- Abrocitinib 100 mg, Abrocitinib 200 mg
- Where
- 15 sites in India
- Volunteers
- 200 people
- Sponsor
- Pfizer
Atopic Dermatitis
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
This is a multicentre, prospective, non-interventional study that aims to describe the treatment patterns of in Atopic dermatitis (AD) patients aged 6 months to 11 years old in Spain: patients' characteristics, disease…
- Trial name
- PROADAP (NCT06415175)
- Testing
- Dupilumab
- Where
- 15 sites in Spain
- Volunteers
- 143 people
- Sponsor
- Sanofi
Atopic Dermatitis (AD)
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis
This is an operationally seamless Phase II/III, multicenter, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07784816
- Testing
- TLL-018 tablets
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Dermatitis Atopic
Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
Primary Objective: To characterize the patients who receive Dupixent® (dupilumab) for AD in a real-world setting, with respect to their medical history, socio-demographic and disease characteristics, and prior and concomitant…
- Trial name
- GLOBOSTAD (NCT03992417)
- Testing
- Dupilumab SAR231893 (REGN668)
- Where
- 105 sites in Argentina, Australia and 20 more
- Volunteers
- 955 people
- Sponsor
- Sanofi
Atopic Dermatitis (AD), SCORAD Index(15-25)
In-Use Tolerance & Efficacy Study Under Dermatological Control of Sunscreen in Adults With Atopic Dermatitis Skin
This study evaluates a broad-spectrum SPF50+ sunscreen on 42 adults with Atopic Dermatitis, measuring skin tolerance and barrier function.
- Trial name
- NCT07194421
- Testing
- Sunscreen RV4620A RP2552
- Where
- Mauritius
- Volunteers
- 42 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis (AD)
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis
This study is an Ic/II phase clinical trial conducted in Chinese subjects with moderate to severe atopic dermatitis. The phase Ic study is a randomized, open label, parallel group design, mainly evaluating the safety and…
- Trial name
- NCT06931990
- Testing
- LT-002-158 tablets
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Healthy Volunteer, Atopic Dermatitis
A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases.
- Conditions
- Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
- Trial name
- NCT04772885
- Testing
- KT-474
- Where
- 14 sites in United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Kymera Therapeutics, Inc.
Atopic Dermatitis
A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable
The main objective of the trial is to evaluate the efficacy of 2 dose regimens of dupilumab compared to placebo, administered with concomitant topical corticosteroids (TCS), in adult patients with severe AD who are not adequately…
- Trial name
- NCT02755649
- Testing
- Dupilumab
- Where
- 73 sites in Austria, Belgium and 8 more
- Volunteers
- 325 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis (AD)
A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis
This Phase 1 study will assess NOR-101, an investigational study drug, in two parts. Part 1 is a randomized, blinded study comparing single and multiple doses of NOR-101 with placebo in healthy adults.
- Trial name
- POLARIS-1 (NCT07904689)
- Testing
- NOR-101
- Where
- Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- North Immunology Inc.
Dermatitis, Atopic
A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
The purpose of this non-interventional study is to learn about the safety and effectivness of Cibinqo Tablet for the possible treatment of atopic dermatitis (AD). AD is a long-lasting itchy red rash, caused by a skin reaction.
- Trial name
- NCT05391061
- Testing
- Abrocitinib
- Where
- South Korea
- Volunteers
- 1,100 people
- Sponsor
- Pfizer
Atopic Dermatitis
Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)
The purpose and (primary) objectives of this study are to evaluate the efficacy, safety, and tolerability of TS-022 in adults with atopic dermatitis who have moderate to very severe pruritus (itching), following a 28-day regimen…
- Trial name
- NCT00914186
- Testing
- TS022, Vehicle
- Where
- 15 sites in United States
- Volunteers
- 122 people
- Sponsor
- Taisho Pharmaceutical R&D Inc.
Atopic Dermatitis (AD)
Efficacy Study of a Repairing Cream in Atopic Dermatitis
The application of DermControl®, a repair cream based on hyaluronic acid, sh-oligopeptide-1 and polyphenols, in combination with topical corticosteroids, could help to improve epidermal barrier function in patients with atopic…
- Trial name
- NCT07742241
- Testing
- Dermcontrol, cream based on hyaluronic acid and sh-oligopeptide-1
- Where
- Spain
- Volunteers
- 116 people
- Sponsor
- Instituto de Investigacion Biotecnologica, Farmaceutica y Medicamentos Huerfanos, S.L.
Atopic Dermatitis
Assessment of Pruritus Improvement With Pimecrolimus Treatment on the Areas Affected by Mild-to-moderate AD, in Patients 2- to 11- Year-old
The purpose of this study is to assess the efficacy and safety of pimecrolimus cream 1% in relation to the improvement of pruritus in pediatric patients (2- to 11- year-old) with mild to moderate atopic dermatitis.
- Trial name
- NCT00510003
- Testing
- Pimecrolimus
- Where
- Spain
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals